Lok Sabha Question No. 2084 (UNSTARRED), answered on 2017-07-28
Subject: Research and Development in Pharma Sector
Ministry: HEALTH AND FAMILY WELFARE
Asked by: PRAHLAD SINGH PATEL

## GOVERNMENT OF INDIA MINISTRY OF HEALTH AND FAMILY WELFARE DEPARTMENT OF HEALTH AND FAMILY WELFARE

LOK SABHA UNSTARRED QUESTION NO. 2084 TO BE ANSWERED ON  28 TH JULY, 2017

## RESEARCH AND DEVELOP MENT IN PHARMA SECTO R

## 2084. SHRI PRAHLAD SINGH PATEL :

Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

- (a) whether the Government is giving highest consideration to R&D in pharma sector;
- (b) if so, the details thereof and if not, the reasons therefor;
- (c) the budget allocated to the Central Drug Research Institute (CDRI) during the last three year and the current year;
- (d) whether the Government is considering involvement of private sector for developing drugs in order to fight acute diseases in the country;
- (e) if so, the details thereof and if not, the reasons therefor; and
- (f) the steps taken/ to be taken by the Government in this regard?

## ANSWER THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (SHRI FAGGAN SINGH KULASTE)

- (a)  &  (b): The  Department  of  Science  and  Technology  (DST)  under  Drugs  and Pharmaceuticals Research Programme (DPRP), has been supporting R&D projects in modern Indian System of Medicines since 1994 - 95 as collaborative projects (public private partnership and facility pro jects to academic institutions/national laboratories to cater to the needs o Pharma Industries. During 2004 - 05, DST extended support to Indian Pharma industry for R&D projects in drug development. From 2008 - 09 onwards, this programme is extending g rants - in - aid to Indian pharmaceutical industries for clinical trials for neglected diseases such as Tu Malaria, Kala - Azar, Filariasis, etc. The major objectives of the programme are:

- To synergise the strengths of publicly funded R&D institutions and Indian Pharmaceutical Industry;

Contd……..

- To  create  an  enabling  infrastructure,  mechanisms  and  linkages  to  facilitate  new development;
- To stimulate skill development of human resources in R&D for pharmaceuticals; and
- To extend soft loan for Pharma industrial R&D projects.

In  addition  to  the  above,  Council  of  Scientific  &  Industrial  Research  (CSIR)  has pursuing  R&D  activities  in  the  domain  of  drugs  and  pharmaceuticals  with  the  emphasis affordable healthc are. Further, Indian Council of Medical Research (ICMR) has been supportin research (in the area of pharma sector) through extramural research as adhoc projects, fe projects, Task Force projects and has established Centres of Advanced Research in Pre- clinical & Clinical Pharmacology with a view to setting up National facilities for the developm New Chemical entities.

(c): Budget allocated to CDRI, Lucknow during the last three years and the current year below:

| Financial Year   |   2014- 15 |   2015- 16 |   2016- 17 |   2017- 18* |
|------------------|------------|------------|------------|-------------|
| Allocation       |    179.789 |     179.13 |    160.497 |      66.788 |

(d) to (f):As detailed in (a) & (b) above, DPRP focuses on collaboration projects includ Public Private Partnership (PPP).

………………

drugs and